Flibanserin

• CAT Number: I002195
• CAS Number: 167933-07-5
• Molecular Formula: C20H21F3N4O
• Molecular Weight: 390.40
• Purity: ≥95%
• Synonyms: 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
• InChI: InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
• InChIKey: PPRRDFIXUUSXRA-UHFFFAOYSA-N
• SMILES: C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F

Flibanserin（Cat No.:I002195）is a non-hormonal medication with the molecular formula C20H21F3N4O, approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally by modulating serotonin, dopamine, and norepinephrine levels—acting as a 5-HT1A receptor agonist and 5-HT2A antagonist—to restore balance in neurotransmitters involved in sexual desire. Flibanserin is taken orally, typically once daily at bedtime. Common side effects include dizziness, fatigue, nausea, and somnolence. Alcohol use is contraindicated due to the risk of severe hypotension and syncope, and regular monitoring is advised during treatment.

Reference

[1]. Fayed M, et al. Insights into Flibanserin Oxidative Stress Degradation Pathway: In Silico – In Vitro Toxicity Assessment of Its Degradates[J]. New Journal of Chemistry, 2021.

[2]. Invernizzi RW, et al. A potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8.
[Content Brief]

[3]. Gelez H, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52.
[Content Brief]

[4]. Podhorna J, et al. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. Br J Pharmacol. 2000 Jun;130(4):739-46.
[Content Brief]

[5]. Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017 Jan;8(1):16-25.
[Content Brief]